FLU – v
Jump to...

FLU-v Universal Flu Vaccine

FLU-v is a broad spectrum vaccine against multiple flu strains using a proprietary “universal flu” technology. It was acquired by hVIVO as part of its joint venture investment in the company, Imutex, in April 2016.

Influenza is a global health challenge. The development of a universal flu vaccine is a key public health priority identified by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) in the United States.

Elderly populations vulnerable to flu

Influenza viruses are one of the major infectious disease threats to the human population owing to both the health impact of annual influenza and the tremendous global consequences of influenza pandemics. Seasonal vaccines typically target specific strains and seasonal flu vaccine formulations will vary by year based on WHO recommendations. These vaccines have had limited effectiveness (between 10% and 60%) during the past 10 years, highlighting the innate variability in circulating flu strains from year to year. It indicates the ongoing susceptibility from virulent pandemic strains, such as what was experienced during the flu pandemic in 2009 where 8,700-18,300 died.

Young boy with temperature , a key symptom of flu

A more universal flu vaccine that can target broader set of viral targets will be a useful tool for reducing these risks and providing potential protection across seasons, reducing costs and risks from annual vaccination each year.


Medical monitoring during clinical trials is criticalFLU-v is a broad spectrum vaccine against multiple flu strains through a proprietary “universal flu” technology that targets conserved internal proteins common to all flu viruses to activate T and B-cells, key components of the human immune system response. The success of such an approach would eliminate the sensitivity to strain variability seen with traditional vaccines and promote single vaccine coverage for all flu strains.


Stage of development

Working closely with The National Institute of Allergy and Infectious Diseases (NIAID), Imutex are leveraging the hVIVO and NIAID platforms to conduct a clinical studies of FLU-v to evaluate the efficacy and safety of this novel vaccine.

Imutex Ltd

Imutex Ltd is a joint venture formed between hVIVO and SEEK Group with a focus currently on a universal flu vaccine (and also a Zika vaccine).

On 22 April 2016, hVIVO plc announced the joint venture investment with the SEEK Group (“SEEK”) to develop vaccines against influenza (flu) and mosquito-borne diseases, such as Zika and other flaviviruses. The joint venture investment in the new company Imutex Limited (“Imutex”) strengthens hVIVO’s commercial flu portfolio and expands it into the adjacent therapeutic area of mosquito-borne diseases, with an immediate and additional focus on Zika.

To find out more about the product developments, both in influenza vaccine development (FLU-v) as outlined here and also in Zika vaccine development (AGS-v), please visit the Imutex website: www.imutex.com

Contact Us

If you are interested to find out more about these and other hVIVO developments and innovations, and how there may be a collaborative or partnering opportunity with your organisation, then please use the “Contact Us” form on this website.

Get in touch

Give us a call, or drop us an email. We'd love to hear from you!

Get in touch now